![]() The DRG's structure along the spinal column is densely populated with nerves that transmit sensory information to the central nervous system, making it an ideal target for treating chronic pain.ĭRG stimulation offers hopeful treatment for a broad group of people experiencing Complex Regional Pain Syndrome (CRPS), or nerve damage caused by an injury. The DRG is the body's center for addressing chronic pain, containing cell bodies of primary sensory neurons that undergo pathophysiologic changes with chronic pain. By blocking or disrupting pain signals transmitted via the DRG, the therapy often helps people living chronic pain, often described as people experiencing pain every day for six months or longer than would generally be expected for recovery to a specific disease, injury or surgery. "I'm 58 and I want to ski till I'm 90."Ībbott's Proclaim DRG system has been shown in more than a dozen clinical studies to provide superior pain relief to patients with neuropathic conditions currently underserved by other forms of chronic pain therapy, including chronic pain following hernia repair, total joint replacements or amputation. DRG therapy has reduced the nerve pain enough that he doesn't need to be on any nerve-pain medications. "It's completely changed how I move and I'm able to move through life," Lawless says. The 58-year-old from Maine went from barely being able to get out of bed to living his dream of backcountry skiing once he began Abbott's DRG treatment in December 2015 to treat his chronic leg pain. This neurostimulation therapy is specifically designed to target the dorsal root ganglia, and has been clinically proven to provide superior pain relief over traditional tonic spinal cord stimulation (SCS), according to a 2017 study published in Pain.įor Tony Lawless, the technology has turned his life around. by 2022 – and Abbott’s most recent acquisitions in the space give its portfolio a powerful position.Ībbott's leadership in addressing chronic pain centers on its industry-leading innovation around Dorsal Root Ganglion (DRG) stimulation. Market Research Engine estimates an 11 percent annual growth rate for the sector – reaching $11 billion annually in the U.S. neuromodulation market continues to expand rapidly, in part because of renewed interest in non-drug treatment alternatives. The portfolio offers devices to address a problem that affects as many as 1.5 billion people worldwide – more than heart disease, cancer and diabetes combined. The confluence of an increasing number of chronic pain cases and the alarming rise in opioid abuse has brought a new focus on non-drug treatment approaches for chronic pain, and Abbott has taken the lead in developing life-changing technologies that let patients manage their own treatments.Ī key part of Abbott's fast-growing neuromodulation business, the company's products aim to relieve pain and enable patients to live their best lives.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |